Drugs, sex, money and power: An HPV vaccine case study

DSpace/Manakin Repository

Search OPUS


Advanced Search

Browse

My Account

Show simple item record

dc.contributor.author Haas, MR
dc.contributor.author Ashton, T
dc.contributor.author Blum, K
dc.contributor.author Christiansen, T
dc.contributor.author Conis, E
dc.contributor.author Crivelli, L
dc.contributor.author Lim, M
dc.contributor.author Lisac, M
dc.contributor.author MacAdam, M
dc.contributor.author Schlette, S
dc.date.accessioned 2010-05-28T09:56:03Z
dc.date.issued 2009-01
dc.identifier.citation Health Policy, 2009, 92 (2-3), pp. 288 - 295
dc.identifier.issn 0168-8510
dc.identifier.other C1 en_US
dc.identifier.uri http://hdl.handle.net/10453/10400
dc.description.abstract In this paper we compare the experiences of seven industrialized countries in considering approval and introduction of the world's first cervical cancer-preventing vaccine. Based on case studies, articles from public agencies, professional journals and newspapers we analyse the public debate about the vaccine, examine positions of stakeholder groups and their influence on the course and outcome of this policy process. The analysis shows that the countries considered here approved the vaccine and established related immunization programs exceptionally quickly even though there still exist many uncertainties as to the vaccine's long-term effectiveness, cost-effectiveness and safety. Some countries even bypassed established decision-making processes. The voice of special interest groups has been prominent in all countries, drawing on societal values and fears of the public. Even though positions differed among countries, all seven decided to publicly fund the vaccine, illustrating a widespread convergence of interests. It is important that decision-makers adhere to transparent and robust guidelines in making funding decisions in the future to avoid capture by vested interests and potentially negative effects on access and equity.
dc.publisher Elsevier
dc.relation.hasversion Accepted manuscript version en_US
dc.relation.isbasedon 10.1016/j.healthpol.2009.05.002
dc.rights NOTICE: this is the author’s version of a work that was accepted for publication in Health Policy. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Health Policy, [VOL 92, ISSUE 2-3, (2009)] DOI: http://dx.doi.org/10.1016/j.healthpol.2009.05.002 en_US
dc.subject Health Policy & Services
dc.subject Health Policy & Services
dc.title Drugs, sex, money and power: An HPV vaccine case study
dc.type Journal Article
dc.parent Health Policy
dc.journal.volume 2-3
dc.journal.volume 92
dc.journal.number 2-3 en_US
dc.publocation Amsterdam en_US
dc.identifier.startpage 288 en_US
dc.identifier.endpage 295 en_US
dc.cauo.name BUS.Centre for Health Economics Research and Evaluation en_US
dc.conference Verified OK en_US
dc.for 160508 Health Policy
dc.personcode 020119 en_US
dc.personcode 0000049456 en_US
dc.personcode 0000049457 en_US
dc.personcode 0000049458 en_US
dc.personcode 0000049459 en_US
dc.personcode 0000049471 en_US
dc.personcode 0000049460 en_US
dc.personcode 0000049461 en_US
dc.personcode 0000049462 en_US
dc.personcode 0000049463 en_US
dc.percentage 100 en_US
dc.classification.name Health Policy en_US
dc.classification.type FOR-08 en_US
dc.edition en_US
dc.custom en_US
dc.date.activity en_US
dc.location.activity en_US
dc.description.keywords en_US
pubs.embargo.period Not known
pubs.organisational-group /University of Technology Sydney
pubs.organisational-group /University of Technology Sydney/Faculty of Business
pubs.organisational-group /University of Technology Sydney/Strength - Health Economics and Research Evaluation


Files in this item

This item appears in the following Collection(s)

Show simple item record